ContraFect

ContraFect FCF CAGR 5Y

The FCF CAGR (5 Year) of ContraFect (CFRXQ) as of Oct 19, 2026 is 13.41 %.

FCF CAGR 5Y

13.41 %

Last updated:

FCF CAGR (5 Year) of ContraFect is 2022 13.41 % . FCF CAGR (5 Year) of ContraFect was 2021 - . It decreases by % lower compared to the previous year.

The ContraFect FCF CAGR 5Y history

The ContraFect FCF CAGR 5Y history
YEARFCF CAGR 5YYoY
13.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ContraFect Stock analysis

What does ContraFect do? ContraFect Corp, based in Yonkers, New York, is a clinical-stage biotechnology company focused on developing direct lytic agents (DLAs) such as lysins and amurin peptides to treat life-threatening antibiotic-resistant infections. The company, listed in 2014, employs 23 people and is advancing its lead candidate exebacase (CF-301) for MRSA bloodstream infections and chronic prosthetic joint infections, alongside CF-370 targeting gram-negative bacteria. ContraFect is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ContraFect stock

FCF CAGR (5 Year) of ContraFect is 13.41 % in 2022.

On Eulerpool you can find the complete historical development of FCF CAGR (5 Year) ContraFect since 2006 – with annual values, charts, and detailed analysis.

The 5-year FCF CAGR shows the compound annual growth rate of free cash flow over five years.

To evaluate FCF CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF CAGR (5 Year).

FCF CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track FCF CAGR (5 Year)'s ContraFect historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — ContraFect

All Key Metrics — ContraFect